ClinicalTrials.gg
CompletedNCT00325780Updated Feb 2, 2010Results posted

Long-Term Extension Study of Pitavastatin in Patients With Primary Hypercholesterolemia or Combined Dyslipidemia

A Phase 3 interventional study of Pitavastatin in Hypercholesterolemia and Dyslipidemia, sponsored by Kowa Research Europe. Completed at 186 sites in 13 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2010-02-02.

Sponsored by Kowa Research Europe (part of Kowa Company, Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,355
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing pitavastatin in Hypercholesterolemia — none open to participants now, none under way, none of them phase 3. pitavastatin · Hypercholesterolemia.

Enrollment
Largest of 19
1,355 · median 200
Started
2006
with 2 others
Phase 3
9 of 19
none open now
Registered
6th of 19
by date
Lead sponsor
7 of 19
Kowa Research Europe

Among the 19 studies testing pitavastatin in Hypercholesterolemia, this one has the largest enrollment, is one of 3 that started in 2006, is one of 9 in phase 3, and was the 6th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

None of the 19 studies testing pitavastatin in Hypercholesterolemia is open now. The open studies under Hypercholesterolemia, anywhere →

About pitavastatin

pitavastatin: first FDA approval 2009 (LIVALO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing pitavastatin in Hypercholesterolemia as a file.
02

Study summary

This study is a long-term follow-up protocol for patients who participated in study NK-104-3.01EU or study NK-104-3.02EU.

Read the detailed description

Patients from the NK-104-3.01EU and NK-104-3.02EU studies will continue to receive either pitavastatin or the comparator statin for 1 year.

03

Conditions studied

  • Hypercholesterolemia
  • Dyslipidemia

Keywords

  • Kowa
  • Hypercholesterolemia
  • dyslipidemia
  • pitavastatin
  • NK-104
  • Hypercholesterolemia or combined dyslipidemia
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients have completed 12 weeks of treatment in Study NK-104-301 (NCT00249249) or NK-104-302 (NCT00309777)
  • Patients who have not developed any treatment emergent and, in the opinion of the investigator, related adverse event (AE) of clinical significance where the investigator is uncomfortable with continuing the patient on therapy with pitavastatin.
  • Patients who have been following a fat and cholesterol restrictive diet.

Exclusion criteria

Exclusion Criteria:

  • Any conditions which may cause secondary dyslipidemia should be reassessed at the beginning of the follow-up study.
  • Uncontrolled diabetes mellitus should be reassessed at the beginning of the follow-up study.
  • Abnormal pancreatic, liver, or renal function
  • Abnormal serum ALAT//ALT, ASAT/SGOT/AST, or creatine kinase (CK) above the pre-specified level
  • Significant heart disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
1,355 participants (actual)

Study arms

  • Experimental
    Pitavastatin 4 mg QD

    Pitavastatin 4 mg once daily

    Drug: Pitavastatin

Interventions

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)

    Mean percent change from baseline in low-density lipoprotein cholesterol (LDL-C)

    Time frame: Baseline to 52 Weeks

Secondary outcomes

  1. Change From Baseline in Total Cholesterol

    Mean percent change from baseline in total cholesterol

    Time frame: Baseline to 52 weeks

07

Results

Posted Jan 18, 2010

Participant flow

Participant flow — Overall Study
MilestonePitavastatin 4 mg QD
Started1355
Safety population1353
Completed1200
Not completed155

Outcome measures

PrimaryPercent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)

Mean percent change from baseline in low-density lipoprotein cholesterol (LDL-C)

Time frame:
Baseline to 52 Weeks
Reported as:
Mean · percent change
Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)
percent changePitavastatin 4 mg QD
Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)-42.89 ± 16.001
SecondaryChange From Baseline in Total Cholesterol

Mean percent change from baseline in total cholesterol

Time frame:
Baseline to 52 weeks
Reported as:
Mean · percent change
Change From Baseline in Total Cholesterol
percent changePitavastatin 4 mg QD
Change From Baseline in Total Cholesterol-29.59 ± 12.549

Adverse events

Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pitavastatin 4 mg QD—49/1,353 (3.6%)293/1,353 (21.7%)
Most frequent serious events
Showing 10 of 48
Most frequent serious events
EventPitavastatin 4 mg QD
Angina unstableCardiac disorders4/1353
Myocardial infarctionCardiac disorders4/1353
Ischaemic strokeNervous system disorders2/1353
HypertensionVascular disorders2/1353
Acute myocardial infarctionCardiac disorders1/1353
Angina pectorisCardiac disorders1/1353
Atrial fibrillationCardiac disorders1/1353
Coronary artery diseaseCardiac disorders1/1353
Ventricular extrasystolesCardiac disorders1/1353
Ventricular tachycardiaCardiac disorders1/1353
Most frequent other events
Most frequent other events
EventPitavastatin 4 mg QD
Blood creatine phosphokinase increasedInvestigations78/1353
NasopharyngitisInfections and infestations73/1353
MyalgiaMusculoskeletal and connective tissue disorders55/1353
ArthralgiaMusculoskeletal and connective tissue disorders46/1353
InfluenzaInfections and infestations41/1353

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Pitavastatin 4 mg QD
<=18 years0
Between 18 and 65 years941
>=65 years412
Age Continuous
Age Continuous(years)Pitavastatin 4 mg QD
Mean58.6 ± 9.08
Sex: Female, Male
Sex: Female, Male(Participants)Pitavastatin 4 mg QD
Female778
Male575
08

Study locations

186 sites
  • Y Forskning, Bispebjerg Hospital
    Copenhagen Nv, Denmark
  • Copenhagen University Hospital
    Copenhagen, Denmark
  • Medical Center
    Copenhagen, Denmark
  • Frederiks Hospital, Kardiologisk
    Frederiksberg, Denmark
  • Kolesterollaboratoriet
    Hellerup, Denmark
  • CCBR A/S
    Vejle, Denmark
  • Geri-Med Oy
    Helsinki, Finland
  • Kaisaniemen Laakariasema
    Helsinki, Finland
  • Keravan Laakarikeskus
    Helsinki, Finland
  • SOK-Tyoterveyshuolto
    Tampere, Finland
  • TYKS University Hospital
    Turku, Finland
  • Kardiologische Gemeinschaftspraxis Prof. Reifart
    Bad Soden/Taunus, Germany
  • Praxis Dr. Boenninghoff
    Beckum, Germany
  • Gemeinschaftspraxis am Bahnhof
    Berlin-Spandau, Germany
  • Klinische Forschung Berlin Mitte
    Berlin, Germany
  • Pharmakologisches Studienzentum Chemnitz
    Chemnitz, Germany
  • GWT-TUK mbH, Zentrum fur Klinische Studien
    Dresden, Germany
  • Internistische Diabetische Schwerpunktpraxis Dr.
    Frankfurt Am Main, Germany
  • Gemeinschaftspraxis Dr. Krause, Th. Menke
    Goch, Germany
  • Klinische Forschung Hamburg
    Hamburg, Germany
  • Innere Medizin I/Medizinische Klinik
    Heidelberg, Germany
  • Gemeinschaftspraxis H. Holz Dr. Med, K. W. Klingl
    Lampertheim, Germany
  • ZET-Studien GmbH Leipzig
    Leipzig, Germany
  • Internistische Gemeinschaftspraxis
    Mainz, Germany
  • Praxis Dr. Wachter
    Mannheim, Germany
  • Gemeinschaftspraxis Melcherstaette
    Melcherstaette, Germany
  • Gemeinschaftspraxis Dr. Senftleber, Dr. Kohler
    Messkirch, Germany
  • Praxisgemeinschaft im Kleinen Biergrund
    Offenbach/M, Germany
  • Gemeinschaftspraxis Drs. Mockesch
    Weinheim, Germany
  • Intermed Institud fur Klinische Forschung und Arzn
    Wiesbaden, Germany
  • Gemeinschaftspraxis Dr. Emden, Frank Drewes
    Worpswede, Germany
  • Care Hospital
    Andhra Pradesh, 500034, India
  • School of Diabetology, Nizam Institute of Medical Sciences
    Andhra Pradesh, 500082, India
  • Bhagwan Mahaveer Jain Heart Centre
    Bangalore, India
  • Sri Ramachandra Medical College Hospital
    Chennai, India
  • Heart Care Clinic
    Gujarat, 380054, India
  • Apollo Hospitals
    Hyderabad, India
  • CARE Group of Hospitals
    Hyderabad, India
  • St. John's Medical College Hospital
    Karnataka, 560034, India
  • Bathia Hospital
    Maharashtra, 400007, India
  • LTMMC & General Hospital
    Maharashtra, 400022, India
  • Sir J. J. Group of Hospitals
    Maharashtra, 400027, India
  • King Edward Medical College & Hospital
    Maharashtra, 411001, India
  • Ruby Hall Clinic
    Maharashtra, 411001, India
  • Lokmanya Hospital
    Maharashtra, 411033, India
  • PD Hinduja Hospital
    Mumbai, India
  • Sir Gagaram Hospital
    New Delhi, 110060, India
  • Apollo Hospital
    Tamil Nadu, 600006, India
  • Department of Cardiology
    Tamil Nadu, 641004, India
  • Department of Internal Medicine, Soroka Medical Center
    Beersheva, Israel
  • Department of Internal Medicine A, Rambal Medical Center
    Haifa, Israel
  • Department of Internal Medicine, Wolfson Medical Center
    Holon, Israel
  • Center for Research, Hadassah University Hospital
    Jerusalem Ein Kerem, Israel
  • Meir Hospital
    Kfar Saba, Israel
  • Department of Medicine, Hadassah Medical Center
    Mount Scopus Jerusalem, Israel
  • Department of Internal Medicine, Rivka Sieff Medical Center
    Safed, Israel
  • Institute of Metabolic Diseases
    Tel Aviv, Israel
  • Institute of Lipid & Atherosclerosis Research
    Tel Hashomer, Israel
  • Dipartimento di Medicina Clinica e Biotecnologia Applicata
    Bologna, Italy
  • Centro di Ricerca Clinica
    Chieti, Italy
  • Gerontologia e Geriatria - Universita degli Studi
    Ferrara, Italy
  • Dipartimento di Medicina Interna DIMI
    Genova, Italy
  • Universita di Modena e Reggio Emilia, Policlinico
    Modena, Italy
  • Dipartimento di Medicina Clinica e Sperimentale
    Napoli, Italy
  • Medicina Clinica e delle Patologie Emergenti
    Palermo, Italy
  • Dipartimento di Medicina Interna e Scienze Biomediche
    Parma, Italy
  • U.O. Malattie Metaboliche e Diabetologia
    Treviglio, Italy
  • Azienda Ospedaliero-Universitaria
    Trieste, Italy
  • Andromed Breda
    Breda, Netherlands
  • Middellaan 5
    Breda, Netherlands
  • Andromed Eindhoven
    Eindhoven, Netherlands
  • Bomanshof 8
    Eindhoven, Netherlands
  • Andromed Noord
    Groningen, Netherlands
  • Damsterdiep 9
    Groningen, Netherlands
  • Vasculair Onderzoek Centrum Hoorn
    Hoorn, Netherlands
  • Andromed Leiden
    Leiden, Netherlands
  • Doezastraat 1
    Leiden, Netherlands
  • Andromed Nijmegen
    Nijmegen, Netherlands
  • Kamerlingh Onnesstraat 16-18
    Nijmegen, Netherlands
  • Andromed Rotterdam
    Rotterdam, Netherlands
  • Mathenesserlaan 247
    Rotterdam, Netherlands
  • Albert Schweitzer Ziekenhuis
    Sliedrecht, Netherlands
  • Andromed Oost
    Velp, Netherlands
  • Reigerstraat 30
    Velp, Netherlands
  • Rivierenland Tiel
    Wp Tiel, Netherlands
  • Andromed Zoetermeer
    Zoetermeer, Netherlands
  • Parkdreef 142
    Zoetermeer, Netherlands
  • Nyomen Legekontor
    Kongsberg, Norway
  • Radhuset Spesialistsenter
    Oslo, Norway
  • Rikshospitalet - University Hospital
    Oslo, Norway
  • Skedsmo Medisinske Senter A.S.
    Skedsmokorset, Norway
  • Podlaski Osrodek Kardiologii
    Bialystok, Poland
  • NZOZ GCP Dobra Praktyka Lekaska
    Gruziadz, Poland
  • NZOZ Terapia Optima
    Katowice, Poland
  • NZOZ Esculap, Przychodnia Lekary Rodzinnych
    Losice, Poland
  • NZOZ Centrum, Poradnia Kardiologiczna
    Siedlce, Poland
  • Spec. Gab. Lek. Internistyczno-Kardiologicznly
    Tarnow, Poland
  • Woj.Szp.Spec.Nr 1 im. Prof. J. Gasinskiego
    Tychy, Poland
  • Instytut Zywnosci i Zywienia
    Warszawa, Poland
  • Lecznica PROSEN SMO
    Warszawa, Poland

Showing the first 100 of 186 sites across 13 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Ose L, Budinski D, Hounslow N, Arneson V. Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia. Atherosclerosis. 2010 May;210(1):202-8. doi: 10.1016/j.atherosclerosis.2009.12.009. Epub 2009 Dec 11. Erratum In: Atherosclerosis. 2010 Oct;212(2):704. PubMed 20080236 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2006, a primary completion of Nov 2007 and a completion of Nov 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2010, 2 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2006
First posted
May 15, 2006
Start
Jul 2006
Primary completionActual
Nov 2007
CompletionActual
Nov 2007
Results first posted
Jan 18, 2010
Last update
Feb 2, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00325780
First posted
May 15, 2006
Start date
Jul 2006
Primary completion
Nov 2007
Completion
Nov 2007
Results posted
Jan 18, 2010
Last update
Feb 2, 2010

Study contacts

Dragos Budinski, Med Dr.
study director · Medical Director

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pitavastatin

Start the discussion